[NCHC] Earnings Report Shows Gilead Can Lower Sovaldi's Unsustainable Price

Statement from the National Coalition on Health Care’s President and CEO John Rother on the latest quarterly earnings report from Gilead Sciences, Inc., manufacturer of the hepatitis C drug Sovaldi:  

“It’s clear Gilead has plenty of room to reduce the $1000 per pill price in order to ensure patients have access to this critical treatment. It’s this sort of pricing for drugs needed by millions of Americans that is putting unsustainable pressure on patients and the health care system as a whole.”